The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AdvanTIG-105: A phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).
 
Se Hyun Kim
Consulting or Advisory Role - Guardant Health; Ono Pharmaceutical; Yuhan
 
Gyeong-Won Lee
No Relationships to Disclose
 
Byoung Yong Shim
Consulting or Advisory Role - AstraZeneca; Bion; Guardant Health; J Ints Bio; Pfizer; Takeda
Research Funding - Yuhan
 
David R. Spigel
Leadership - ASCO (Inst)
Consulting or Advisory Role - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Evidera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Peloton Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Seagan (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis
 
Her-Shyong Shiah
No Relationships to Disclose
 
Sophia Frentzas
Consulting or Advisory Role - GOG Foundation; MSD Oncology
 
Harry H. Yoon
Honoraria - BeiGene (Inst)
Travel, Accommodations, Expenses - BeiGene (Inst)
 
Feng Wang
No Relationships to Disclose
 
Meili Sun
No Relationships to Disclose
 
Timothy Dudley Clay
Stock and Other Ownership Interests - ClinicIQ
Honoraria - Lilly; Specialised Therapeutics; Wiley
Consulting or Advisory Role - AstraZeneca/MedImmune; Cipla; Foundation Medicine; Merck KGaA; Takeda
Speakers' Bureau - AstraZeneca/MedImmune; MSD
Research Funding - Abbvie (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Clovis Oncology (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Exelixis (Inst); Immutep (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Hao Zheng
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene
 
Wei Tan
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Ziqi Zhou
Employment - BeiGene
 
Ruihua Wang
Employment - BeiGene Shanghai
Stock and Other Ownership Interests - BeiGene
 
Yi Ba
No Relationships to Disclose